Skip to main content
SpringerLink
Log in

Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: A retrospective study

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Antithyroid drugs may be proposed as the first-line therapy for hyperthyroidism due to Graves’ disease since some patients undergo prolonged remission after drug withdrawal. On the other hand, some studies, though controversial, indicated that methimazole (MMI) has some immunomodulating activity. We retrospectively analyzed 384 consecutive patients newly diagnosed with Graves’ disease in the years 1990–2002 to ascertain whether long-term therapy with low doses of MMI may prevent relapse of thyrotoxicosis. Two hundred and forty-nine patients were included in our study. The date of reduction of MMI dose to 5 mg/day was considered time 0 for survival analysis. In 121 MMI was discontinued in less than 15 months after time 0 (group D), while in the remaining 128 a daily MMI 2.5–5 mg dose was maintained (group M). One hundred and thirty-five patients were excluded for inadequate response to MMI, relapse of thyrotoxicosis that could be related to an improper withdrawal or reduction of MMI, inadequate or too short follow-up, iodide contamination, steroid or interferon therapy, pregnancy or post-partum. D and M groups did not differ for clinical and hormonal parameters except age, which was lower in D (p=0.019). Age > vs < 35 yr was relevant in survival analysis; therefore patients were divided in 2 groups according to this age cut-off. In younger patients relapse of thyrotoxicosis occurred in 15 patients of group D 2.4–39.6 months (median 19.0) after time 0, and 8 M after 5.9–40.0 (21.3) months, while 14 D and 5 M maintained euthyroidism until the end of the observation after 31.8–95.3 (56.6) months and 30.4–62.1 (46.5) months, respectively. Survival analysis indicated that the risk of relapse was similar in group D and M. In older patients relapse of thyrotoxicosis occurred in 40 patients of group D after 8.2–65.8 (25.4) months and 29 M after 5.8–62.5 (22.4) months, while 52 D and 86 M maintained euthyroidism until the end of the observation, 20.1–168.0 (46.7) months and 24.1–117.4 (53.4) months respectively. Survival analysis indicated that the risk of relapse was increased in group D. Therefore long-term treatment with low doses of MMI seems to prevent relapse in Graves’ disease in patients above 35 yr of age. This should be confirmed in a prospective study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mori T, Sugawa H, Kosugi S, Ueda M, Hai N, Matsuda A. Recent trends in the management of Graves’ hyperthyroidism in Japan: opinion survey results, especially on the combination therapy of antithyroid drug and thyroid hormone. Endocr J 1997, 44: 509–17.

    Article  PubMed  CAS  Google Scholar 

  2. Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves’ disease. Endocrinol Metab Clin North Am 1998, 27: 225–47.

    Article  PubMed  CAS  Google Scholar 

  3. Ljunggren JG, Törring O, Wallin G, et al. Quality of life aspects and costs in treatment of Graves’ hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 1998, 8: 653–9.

    Article  PubMed  CAS  Google Scholar 

  4. Escobar-Jiménez F, Férnandez-Soto ML, Luna-López V, Quesada-Charneco M, Glinoer D. Trends in diagnostic and therapeutic criteria in Graves’ disease in the last 10 years. Postgrad Med J 2000, 76: 340–4.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Weetman AP. Controversy in thyroid disease. J R Coll Physicians Lond 2000, 34: 374–80.

    PubMed  CAS  Google Scholar 

  6. Zantut-Wittmann DE, Tambascia MA, da Silva Trevisan MA, et al. Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves’ disease. Thyroid 2001, 11: 575–80.

    Article  PubMed  CAS  Google Scholar 

  7. Montani V, Shong M, Taniguchi SI, et al. Regulation of major histocompatibility class II gene expression in FRTL-5 thyrocytes: opposite effects of interferon and methimazole. Endocrinology 1998, 139: 290–302.

    PubMed  CAS  Google Scholar 

  8. Mozes E, Zinger H, Kohn LD, Singer DS. Spontaneous autoimmune disease in (NZB × NZW)F1 mice is ameliorated by treatment with methimazole. J Clin Immunol 1998, 18: 106–13.

    Article  PubMed  CAS  Google Scholar 

  9. Volpé R. Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review. Thyroid 1994, 4: 217–23.

    Article  PubMed  Google Scholar 

  10. Allannic H, Fauchet R, Orgiazzi J, et al. Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990, 70: 675–9.

    Article  PubMed  CAS  Google Scholar 

  11. Tajiri J, Noguchi S, Morita M, Tamaru M, Marukami N. Antithyroid drug therapy for Graves’ hyperthyroidism: is long-term administration of a small maintenance dose necessary? Endocrinol Jpn 1991, 38: 223–7.

    Article  PubMed  CAS  Google Scholar 

  12. García-Mayor RV, Páramo C, Luna Cano R, Pérez Mendez LF, Galofré JC, Andrade A. Antithyroid drug and Graves’ hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest 1992, 15: 815–20.

    Google Scholar 

  13. Maugendre D, Gatel A, Campion L, et al. Antithyroid drugs and Graves’ disease-prospective randomized assessment of long-term treatment. Clin Endocrinol 1999, 50: 127–32.

    Article  CAS  Google Scholar 

  14. Benker G, Reinwein D, Kahaly G, et al. Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf) 1998, 49: 451–7.

    Article  CAS  Google Scholar 

  15. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996, 334: 220–4.

    Article  PubMed  CAS  Google Scholar 

  16. Lucas A, Salinas I, Rius F, et al. Medical therapy of Graves’ disease: does thyroxine prevent recurrence of hyperthyroidism? J Clin Endocrinol Metab 1997, 82: 2410–3.

    PubMed  CAS  Google Scholar 

  17. Grebe SK, Feek CM, Ford HC, et al. A randomized trial of short-term treatment of Graves’ disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin Endocrinol 1998, 48: 585–92.

    Article  CAS  Google Scholar 

  18. Rittmaster RS, Abbott EC, Douglas R, et al. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves’ disease. J Clin Endocrinol Metab 1998, 83: 814–8.

    PubMed  CAS  Google Scholar 

  19. Pujol P, Osman A, Grabar S, et al.TSH suppression combined with carbimazole for Graves’ disease: effect on remission and relapse rates. Clin Endocrinol (Oxf) 1998, 48: 635–40.

    Article  CAS  Google Scholar 

  20. Raber W, Kmen E, Waldhäusl W, Vierhapper H. Medical therapy of Graves’ disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. Eur J Endocrinol 2000, 142: 117–24.

    Article  PubMed  CAS  Google Scholar 

  21. Glinoer D, de Nayer P, Bex M; Belgian Collaborative Study Group on Graves’ Disease. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with Antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001, 144: 475–83.

    Article  PubMed  CAS  Google Scholar 

  22. Saggiorato E, Arecco F, Mussa A, et al; Piedmont Goiter Study Committee. Goiter prevalence and urinary iodine status in urban and rural/mountain areas of Piedmont region. J Endocrinol Invest 2006, 29: 67–73.

    Article  PubMed  CAS  Google Scholar 

  23. Dayan CM. Interpretation of thyroid function tests. Lancet 2001, 357: 619–24.

    Article  PubMed  CAS  Google Scholar 

  24. Cho BY, Shong MH, Yi KH, Lee HK, Koh CS, Min HK. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves’ disease. Clin Endocrinol (Oxf) 1992, 36: 585–90.

    Article  CAS  Google Scholar 

  25. Perez C, Scrimshaw S, Munoz A. Technique of endemic goitre surveys. Monogr Ser World Health Organ 1960, 44: 369–83.

    PubMed  CAS  Google Scholar 

  26. Carella C, Mazziotti G, Sorvillo F, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 2006, 16: 295–302.

    Article  PubMed  CAS  Google Scholar 

  27. Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 1997, 7: 369–75.

    Article  PubMed  CAS  Google Scholar 

  28. Schott M, Minich WB, Willenberg HS, et al. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves’ disease. Horm Metab Res 2005, 37: 741–4.

    Article  PubMed  CAS  Google Scholar 

  29. Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves’ disease after withdrawal of antithyroid treatment. Horm Metab Res 2005, 37: 745–50.

    Article  PubMed  CAS  Google Scholar 

  30. Nedrebo BG, Holm PI, Uhlving S, et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur J Endocrinol 2002, 147: 583–9.

    Article  PubMed  CAS  Google Scholar 

  31. Yamada T, Aizawa T, Koizumi Y, Komiya I, Ichikawa K, Hashizume K. Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves’ disease. J Am Geriatr Soc 1994, 42: 513–6.

    PubMed  CAS  Google Scholar 

  32. Kashiwai T, Hidaka Y, Takano T, et al. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves’ disease. Endocr J 2003, 50: 45–9.

    Article  PubMed  CAS  Google Scholar 

  33. Chiovato L, Barbesin G, Pinchera A. Graves’ disease. In: DeGroot LJ, Jameson JL (eds), Endocrinology, 4th edition. Philadelphia, USA: Saunders Co. 2001, 1422.

    Google Scholar 

  34. Barrio R, López-Capapé M, Martinez-Badás I, Carrillo A, Moreno JC, Alonso M. Graves’ disease in children and adolescents: response to long-term treatment. Acta Paediatr 2005, 94: 1583–9.

    Article  PubMed  Google Scholar 

  35. Akuzawa M, Murakami M, Yamada M, Satoh T, Shimizu H, Mori M. Preserved activation of thyrotropin receptor antibody to stimulate thyroid function despite long-term treatment in euthyroid patients with Graves’ disease. Eur J Endocrinol 1998, 138: 281–5.

    Article  PubMed  CAS  Google Scholar 

  36. Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves’ disease. J Clin Endocrinol Metab 1994, 78: 98–102.

    PubMed  CAS  Google Scholar 

  37. Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A. Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid 2000, 10: 891–6.

    Article  PubMed  CAS  Google Scholar 

  38. Yamano Y, Takamatsu J, Sakane S, Hirai K, Kuma K, Ohsawa N. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves’ disease. Thyroid 1999, 9: 769–73.

    Article  PubMed  CAS  Google Scholar 

  39. Giovanella L, Ceriani L, Garancini S. Clinical applications of the 2nd generation assay for anti-TSH receptor antibodies in Graves’ disease. Evaluation in patients with negative 1st generation test Clin Chem Lab Med 2001, 39: 25–8.

    CAS  Google Scholar 

  40. Maugendre D, Massart C. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves’ disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol 2001, 54: 89–96.

    Article  CAS  Google Scholar 

  41. Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt-Rasmussen U. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves’ disease. Eur J Endocrinol 2002, 146: 173–7.

    Article  PubMed  CAS  Google Scholar 

  42. Cooper DS. Drug therapy: antithyroid drugs. N Engl J Med 2005, 352: 905–17.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Maria Vittoria Hospital, ASL TO2, Turin, Italy

    E. Mazza MD, S.C., M. Carlini MD, S.C., D. Flecchia, A. Blatto, O. Zuccarini, S. Gamba, S. Beninati & M. Messina

Authors
  1. E. Mazza MD, S.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Carlini MD, S.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Flecchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Blatto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. Zuccarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Gamba
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Beninati
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Messina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Mazza MD, S.C..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mazza, E., Carlini, M., Flecchia, D. et al. Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: A retrospective study. J Endocrinol Invest 31, 866–872 (2008). https://doi.org/10.1007/BF03346433

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346433

Key-words

Search

Navigation